logo
Blood pressure and dementia risk share surprising link, study suggests

Blood pressure and dementia risk share surprising link, study suggests

New York Post23-04-2025
Hypertension, or high blood pressure, is known to have a direct impact on heart attack and stroke risk — but a new study has revealed its surprising link to brain health.
In a large, randomized trial, researchers led by First Hospital of China Medical University discovered that 'intensive blood pressure control' resulted in a 15% reduced dementia risk among participants and a 16% reduced risk of cognitive impairment.
The study included 33,995 people in rural China aged 40 or older who had 'uncontrolled hypertension.'
The participants were divided into two groups.
One received 'usual care,' while the other was assigned to 'trained non-physician community healthcare providers' who prescribed 'titrated antihypertensive medications.'
For the latter group, the medications helped them achieve a systolic blood pressure goal of <130 mm Hg and a diastolic blood pressure goal of <80 mm Hg, according to the study findings in Nature Medicine.
'The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group,' the researchers wrote.
They were also less likely to experience 'serious adverse events.'
3 High blood pressure can impact brain health, according to a new study.
BillionPhotos.com – stock.adobe.com
This was one of the first large-scale, randomized, controlled effectiveness trials to demonstrate a 'significant reduction in all-cause dementia associated with lowering blood pressure,' the researchers concluded.
There were some limitations of the study, the article acknowledged, including the absence of baseline and follow-up cognitive assessments.
Dr. Bradley Serwer — an interventional cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company that offers cardiovascular and anesthesiology services to hospitals — said this study presents an 'intriguing approach' to addressing dementia in individuals with uncontrolled hypertension.
3 'The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group,' the researchers wrote.
LIGHTFIELD STUDIOS – stock.adobe.com
'Unlike studies performed in the United States, this study employed non-physicians to significantly reduce blood pressure in rural China through a 'cluster' blinding method,' Ohio-based Serwer, who was not involved in the study, told Fox News Digital.
'While the study can be subject to scrutiny, it raises a pertinent question: How crucial is modification of cardiovascular risk factors in the development of dementia?'
The primary medications used in the study to lower blood pressure were calcium channel blockers and angiotensin receptor blockers, Serwer noted.
'These commonly prescribed medications have been independently associated with a reduced risk of dementia, irrespective of the magnitude of blood pressure reduction they achieve,' he said.
3 Nearly 34,000 people in rural China over the age of 40 participated in the study.
wutzkoh – stock.adobe.com
'This raises the possibility that the lower rates of dementia observed may be attributed to other beneficial effects of the medications rather than solely to blood pressure reduction.'
To confirm the findings, Serwer said it would be beneficial to include baseline cognitive assessments of the patients and to identify the prevalence of Alzheimer's dementia within the communities.
'The most significant takeaway from this study is the profound importance of addressing blood pressure, cholesterol, smoking and sedentary lifestyles,' the cardiologist said.
'By prioritizing these factors, we not only aim to prevent heart attacks and strokes, but also strive to enhance overall quality of life.'
The study was supported by the National Key Research and Development Program of the Ministry of Science and Technology of China, Chinese Society of Cardiology Foundation, and the Science and Technology Program of Liaoning Province, China.
Fox News Digital reached out to the researchers for comment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Changes In Prior Approval Coming To Traditional Medicare, Medicare Advantage
Changes In Prior Approval Coming To Traditional Medicare, Medicare Advantage

Forbes

time3 hours ago

  • Forbes

Changes In Prior Approval Coming To Traditional Medicare, Medicare Advantage

There were two major announcements recently regarding prior approval of treatments and services for Medicare beneficiaries. In most medical insurance, many treatments won't be covered unless it is approved first by the insurer. It's been a source of controversy for some time. Original Medicare hasn't required prior authorization of treatments and services, with a few exceptions. For most care, providers and the patient agree on a treatment. After the treatment, paperwork for approval and payment is submitted to Medicare. Medicare recently announced a new model program that will test pre-approval. The voluntary model program will test pre-approval for some services and treatments, according to a recent announcement from the Center for Innovation of the Centers for Medicare and Medicaid Services. The model program is seeking medical providers to volunteer for the program from Jan. 1, 2026 through Dec. 31, 2031. The model will be restricted to New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Providers who volunteer and are accepted will agree to seek prior authorization for 17 items and services, including skin substitutes, deep brain stimulation for Parkinson's Disease, impotence treatment, and arthroscopy for knee osteoarthritis. A provider who volunteers for the program can choose not to seek prior approval for a case. There will be a post-treatment review of the case, and the provider will risk not being paid by Medicare for the treatment. CMS initiated the program and selected the services to be covered because of a series of reports showing waste, fraud or abuse in certain areas. For example, Medicare spent up to $5.8 billion in 2022 on unnecessary or inappropriate services that had no clinical benefit, according to the Medicare Payment Advisory Commission. Under the model, providers will submit the same information they currently submit for payment approval after a service is provided to a beneficiary. The difference is that under the model, the information will be submitted earlier and the provider will wait for approval before performing the services. CMS will select companies to receive and review the prior authorizations. It expects that they will use artificial intelligence and other tools in addition to medical professionals to review the submissions. The companies will be paid based on the extent to which they saved the government money by stopping unnecessary services. CMS said it will manage the program to avoid adverse impact on beneficiaries and providers. There was other news about pre-approval, this time involving Medicare Advantage plans. Pre-approval in Medicare Advantage plans has been controversial recently. There have been a number of recent reports and studies that found the authorization process was delaying treatment or causing patients to abandon treatment plans. Other reports indicated that a high percentage of treatments that initially were denied coverage eventually were approved if the patients or their providers appealed the than 50 major insurers who sponsor many types of insurance plans announced that they will voluntarily streamline prior authorization of treatments and services in all insurance markets, including Medicare Advantage plans. The insurers say they plan to have the new process in place by Jan. 1, 2027.

MrBeast Makes Astronomer Joke After Gwyneth Paltrow Video
MrBeast Makes Astronomer Joke After Gwyneth Paltrow Video

Newsweek

time8 hours ago

  • Newsweek

MrBeast Makes Astronomer Joke After Gwyneth Paltrow Video

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. MrBeast, who was recently named the top content creator in the world by Forbes, has reacted to one of the year's most viral stories, the Astronomer Coldplay "kiss-cam scandal." In a post on X, formerly Twitter, MrBeast responded to the company's recent marketing video, which featured Gwyneth Paltrow. Newsweek has reached out to a representative for MrBeast via email for comment. Why It Matters MrBeast's social media post comes after a split-second clip of Astronomer CEO Andy Byron and his colleague Kristin Cabot was shared on social media and promptly broke the internet. The video, first shared by instaagraace on TikTok, has been viewed over 128 million times as of time of writing. Left, MrBeast speaks onstage during YouTube Brandcast 2025 at David Geffen Hall in New York City on May 14, 2025. Right, Gwyneth Paltrow attends the 2025 Breakthrough Prize Ceremony at Barker Hangar in Santa Monica,... Left, MrBeast speaks onstage during YouTube Brandcast 2025 at David Geffen Hall in New York City on May 14, 2025. Right, Gwyneth Paltrow attends the 2025 Breakthrough Prize Ceremony at Barker Hangar in Santa Monica, California, on April 5, 2025. More Taylor Hill/FilmMagic/for YouTube In the clip, the jumbotron lands on the pair and they promptly sprang apart. Coldplay's lead singer Chris Martin, says: "Either they're having an affair or they're just really shy." The pair were later identified as Byron, CEO of the tech firm Astronomer, and Cabot, the company's head of Human Resources. Both have now resigned. What To Know On July 26, Astronomer shared a light-hearted marketing video which capitalizes on the attention that has been brought to the company since the now infamous Coldplay canoodling. The video features Paltrow, Martin's Oscar-winning ex-wife, as a "very temporary spokesperson." MrBeast, real name Jimmy Donaldson, responded to this on X. In a post that has been viewed over 230,000 times, he wrote, "Can I be CEO." Astronomer's board of directors have announced that they will start a formal search for their new chief executive. Company co-founder Pete DeJoy has taken over as interim CEO. He said on Monday that Astronomer has faced an "unusual and surreal" amount of attention in recent days. Astronomer is a New York-based company that helps companies develop, grow, and analyze products using artificial intelligence. MrBeast, whose YouTube channel boasts over 416 million subscribers, is the owner of multiple companies, including Feastables and MrBeast Burger. He has previously shared posts on social media expressing interest in buying the social media platform X from Elon Musk. In June, as part of their list of Top Content Creators, Forbes reported that MrBeast had earnings of $85 million. Back in 2022, Forbes reported the 27-year-old could become the world's "first YouTuber billionaire," reporting at the time that he had a net worth of $500 million. What People Are Saying An Astronomer spokesperson previously told Newsweek in a statement: "Astronomer is committed to the values and culture that have guided us since our founding. Our leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met." What's Next The search for Astronomer's new CEO is ongoing.

BrainSim-X Launches Developer Platform for Neural Simulation Data
BrainSim-X Launches Developer Platform for Neural Simulation Data

Time Business News

time10 hours ago

  • Time Business News

BrainSim-X Launches Developer Platform for Neural Simulation Data

BrainSim-X announced the launch of a developer access program that allows researchers and app developers to integrate brain simulation data into their applications. More information about the platform is available at their official website . The Bangalore-based research initiative said the platform will focus on medical applications, particularly epilepsy research and neurological treatment development. Unlike typical API services, BrainSim-X requires developers to submit applications explaining their intended use cases before gaining access to the platform. Interested developers can request API credentials through their secure portal. The approval process takes approximately one week, with the organization reviewing each application to ensure it aligns with their medical research focus. One developer who has used the platform for three months described it as providing detailed neural activity data that requires significant technical expertise to implement properly. A detailed account of this developer's experience can be found in their comprehensive review . 'The platform generates large amounts of data that require powerful computing resources,' the developer said. 'It's designed for serious medical research rather than general app development.' The organization provides documentation and support for developers working on brain-computer interfaces, neuroscience research projects, and medical applications. Their research findings are available for review in published papers. Real-time data access became available recently, allowing developers to integrate live neural simulation feeds into their applications. The platform is intended for researchers studying brain activity patterns, testing neurological treatments, and developing diagnostic tools. BrainSim-X operates the service through a secure API that provides access to neural simulation data generated by their brain modeling platform. Technical requirements include high-memory computing systems capable of processing large neural datasets. Additional technical insights about the platform's capabilities can be found in this technical analysis . The research initiative says the developer program represents part of their commitment to making brain simulation technology accessible to the global research community. Applications are evaluated based on their potential contribution to medical research and neurological treatment development. BrainSim-X has not disclosed revenue generated from the developer platform, stating that funds support ongoing research activities. The organization expects demand for the platform to grow as more researchers learn about neural simulation applications in medical research. Future platform updates will include enhanced simulation capabilities and additional tools for analyzing neural activity patterns. BrainSim-X says the developer program differentiates it from commercial AI companies by focusing on open research collaboration rather than proprietary technology development. The platform supports research into cognitive enhancement, educational technology, and advanced diagnostic systems. Developers interested in accessing the platform must demonstrate relevant research experience and explain how they plan to use neural simulation data in their projects. BrainSim-X provides training resources to help developers understand neuroscience concepts necessary for effectively using the platform. The organization says it will continue expanding the developer program while maintaining focus on medical and scientific applications. Related Resources TIME BUSINESS NEWS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store